Selective androgen receptor modulators (SARMs) that function as AR antagonists in specific cell types including prostate cancer cells, and selective androgen receptor degraders or down-regulators (SARDs) are being studied for clinical application (Figure 1B) [28,29]. This evidence concerns the gene AR and prostate cancer.